Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?

Veccia, Antonello; Maines, Francesca; Caffo, Orazio

doi:10.1038/nrurol.2017.127

Cited by 2 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, electrophysiological changes, including AF, have been reported in those receiving cancer treatments using exogenous hormonal drugs ( 24 ). Prolonged ADT exposure in an aging populations is associated with increased cardiovascular morbidity ( 25 ). In recent years, the progressive widespread use of novel antiandrogen therapies such as abiraterone and enzalutamide, has also targeted the hormonal axis.…”

Section: Discussionmentioning

confidence: 99%

Prevalence and outcomes of atrial fibrillation in patients suffering prostate cancer: a national analysis in the United States

Pan,

Xu,

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

PurposeAlthough the adverse effects of atrial fibrillation (AF) on cancers have been well reported, the relationship between the AF and the adverse outcomes in prostate cancer (PC) remains inconclusive. This study aimed to explore the prevalence of AF and evaluate the relationship between AF and clinical outcomes in PC patients.MethodsPatients diagnosed with PC between 2008 and 2017 were identified from the National Inpatient Sample database. The trends in AF prevalence were compared among PC patients and their subgroups. Multivariable regression models were used to assess the associations between AF and in-hospital mortality, length of hospital stay, total cost, and other clinical outcomes.Results256,239 PC hospitalizations were identified; 41,356 (83.8%) had no AF and 214,883 (16.2%) had AF. AF prevalence increased from 14.0% in 2008 to 20.1% in 2017 (P < .001). In-hospital mortality in PC inpatients with AF increased from 5.1% in 2008 to 8.1% in 2017 (P < .001). AF was associated with adverse clinical outcomes, such as in-hospital mortality, congestive heart failure, pulmonary circulation disorders, renal failure, fluid and electrolyte disorders, cardiogenic shock, higher total cost, and longer length of hospital stay.ConclusionsThe prevalence of AF among inpatients with PC increased from 2008 to 2017. AF was associated with poor prognosis and higher health resource utilization. Better management strategies for patients with comorbid PC and AF, particularly in older individuals, are required.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and outcomes of atrial fibrillation in patients suffering prostate cancer: a national analysis in the United States

Pan,

Xu,

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Based on this work, diethylstilbestrol (DES) became a standard of care for patients with PCa. DES and other estrogens function by two mechanisms, one by inhibiting the hypothalamus-pituitary-hypogonadal (HPG) axis, and the other by increasing sex-hormone binding globulin (SHBG) [ 31 , 32 ]. More than 90% of the serum testosterone is SHBG-bound with only a fraction being free testosterone and this free testosterone is the functional AR ligand [ 33 , 34 ].…”

Section: Treatments Targeting the Ar Signaling Pathway For Androgen-dmentioning

confidence: 99%

“…Administration of Capesaris to CRPC patients caused a dose-dependent increase in SHBG levels and a decrease in free-testosterone [ 35 ]. Despite the advantage of ER-targeted therapy for PCa, major adverse-effects such as venous thromboembolism and estrogenic proliferative actions on PCa cells contributed to the discontinuation of estrogen-based therapy for advanced PCa [ 31 ].…”

Section: Treatments Targeting the Ar Signaling Pathway For Androgen-dmentioning

confidence: 99%

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer

Narayanan

2020

Asian Journal of Urology

View full text Add to dashboard Cite

Prostate cancer (PCa) accounted for over 300 000 deaths world-wide in 2018. Most of the PCa deaths occurred due to the aggressive castration-resistant PCa (CRPC). Since the androgen receptor (AR) and its ligands contribute to the continued growth of androgen-dependent PCa (ADPCa) and CRPC, AR has become a well-characterized and pivotal therapeutic-target. Although AR signaling was identified as therapeutic-target in PCa over five-decades ago, there remains several practical issues such as lack of antagonist-bound AR crystal structure, stabilization of the AR in the presence of agonists due to N-terminus and C-terminus interaction, unfavorable large-molecule accommodation of the ligand-binding domain (LBD), and generation of AR splice variants that lack the LBD that impede the discovery of highly potent fail-safe drugs. This review summarizes the AR-signaling pathway targeted therapeutics currently used in PCa and the approaches that could be used in future AR-targeted drug development of potent next-generation molecules. The review also outlines the discovery of molecules that bind to domains other than the LBD and those that inhibit both the full length and splice variant of ARs.

show abstract

Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?

Cited by 2 publications

References 8 publications

Prevalence and outcomes of atrial fibrillation in patients suffering prostate cancer: a national analysis in the United States

Prevalence and outcomes of atrial fibrillation in patients suffering prostate cancer: a national analysis in the United States

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer

Contact Info

Product

Resources

About